STING1 and cancer: However, as the IFN-λ locus has been shown to be polymorphic in a subset of cancer patients and patients suffering from infectious diseases (8, 29, 65, 66), moving forward, polymorphisms and differences in IFN-λ gene expression will need to be taken into account when considering clinical STING immunotherapeutic approaches (29, 35, 67, 68).